CJC-1295 with DAC benefits and areas of interest

CJC-1295 with DAC has one demonstrated effect in humans, and it is a hormone effect rather than an outcome. In two randomized, placebo-controlled, double-blind ascending-dose studies in healthy adults aged 21–61, a single subcutaneous injection raised growth hormone (GH) 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9–11 days; the estimated half-life was 5.8–8.1 days (Teichman et al., J Clin Endocrinol Metab 2006). That duration — days, not minutes — is the entire point of the molecule and the entire body of human efficacy evidence for it. No published study has used fat mass, lean mass, strength, sleep quality, or injury recovery as an endpoint.

• Single-dose pharmacodynamics. Four ascending single doses over a 28-day study, with GH and IGF-1 peak concentrations and area under the curve as the primary outcomes (Teichman 2006).

• Repeat dosing. Two or three weekly or biweekly doses over 49 days kept IGF-1 above baseline for as long as 28 days after the last injection. No serious adverse reactions were reported in either study.

• Total human exposure. Across the three published studies FDA was able to identify, 63 healthy adults (87% men) received up to four subcutaneous injections at 30–250 mcg/kg — and 73% of them received exactly one injection (FDA briefing document, PCAC December 2024).

That last figure is the one worth holding onto. The safety and benefit profile of a compound marketed for continuous use rests almost entirely on single doses given to healthy young men two decades ago.

The Drug Affinity Complex is not a slow-release coating. It is a maleimido-modified lysine added to a tetrasubstituted GHRH(1-29) analogue; after injection, that group reacts with the free thiol of cysteine-34 on circulating serum albumin, forming a covalent bond in the bloodstream. In rats, the resulting conjugate produced a four-fold larger GH area under the curve over two hours than unmodified human GRF, remained detectable in circulation beyond 72 hours, and could still be shown bound to albumin 24 hours after injection (Jetté et al., Endocrinology 2005).

The same chemistry has a flagged downside. FDA's reviewers noted that the DAC modification "could also favor the interaction of CJC-1295 DAC with thiol groups in cysteine residues of proteins other than albumin and contribute to off-target effects" — an unresolved question, not a demonstrated harm, but one specific to this molecule rather than to GHRH analogues generally.

The body-composition claims are a chain of inference: CJC-1295 raises GH → GH raises IGF-1 → IGF-1 signalling builds muscle and mobilises fat. The first two links were measured. The third was never tested for this compound in a person.

Two facts constrain how far that chain can be stretched. First, FDA's 2024 evaluation concluded there are "no studies evaluating effectiveness in humans with GHD for any of the evaluated substances," and that patients with complete growth hormone deficiency will not respond to a secretagogue at all, because the drug works by asking a pituitary to do something it can still do. Second, the one trial that enrolled people with a condition — a phase 2 study in HIV- associated visceral obesity — was terminated and never published (NCT00267527), so whatever it found about visceral fat is not in the public record.

• Tesamorelin — the comparison that matters. Also a stabilised GHRH analogue, but FDA-approved, with phase 3 visceral-fat data in HIV lipodystrophy. It is what a GHRH analogue looks like when the development programme finishes.

• CJC-1295 without DAC — the same peptide backbone without the albumin-binding group, so minutes of action instead of days. Not the substance studied by Teichman.

• Sermorelin — plain GHRH(1-29), which was once an approved drug and is the ancestor of both CJC forms.

• Ipamorelin and the GHRPs — a different receptor (ghrelin/GHS-R1a), which is the rationale for the common blend. No controlled human trial of that combination has been published.

For the counterweight, see CJC-1295 with DAC side effects — which is where the 2006 trial death and FDA's nonclinical findings sit.